Laura Rubio-Pérez

7PUBLICATIONS
77CO-AUTHORS
Medical devicesCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 24, 2026
A Drug-Gated, Modular STAb-T Immunotherapy With External Control.

|Oct 27, 2025
Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.

Marina Gómez-Rosel, Laura Rubio-Pérez, Ivana Zagorac

|Mar 16, 2025
A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Aïda Falgàs, Rodrigo Lázaro-Gorines, Samanta Romina Zanetti

|May 28, 2024
Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Laura Rubio-Pérez, Susana Frago, Marta Compte

|Feb 14, 2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Laura Díez-Alonso, Aïda Falgas, Javier Arroyo-Ródenas

|Apr 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood

Pageof 2

Frequent Collaborators

7 joint publications

Luis Álvarez-Vallina

5 joint publications

Belén Blanco

4 joint publications

Laura Díez-Alonso

4 joint publications

Marta Compte